|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.87 USD | -0.12% |
|
+2.99% | +0.74% |
| Feb. 12 | BioMarin Pharmaceutical Inc. Announces Closing of Private Offering of Senior Notes | CI |
| Feb. 12 | BridgeBio's oral drug improves growth in children with dwarfism in late-stage study | RE |
| Capitalization | 11.5B 9.7B 8.85B 8.44B 15.68B 1,044B 16.26B 103B 40.88B 503B 43.14B 42.25B 1,765B | P/E ratio 2025 * |
24.1x | P/E ratio 2026 * | 15.1x |
|---|---|---|---|---|---|
| Enterprise value | 10.08B 8.5B 7.76B 7.39B 13.74B 915B 14.25B 90.13B 35.83B 441B 37.8B 37.03B 1,547B | EV / Sales 2025 * |
3.17x | EV / Sales 2026 * | 2.87x |
| Free-Float |
99.12% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BioMarin Pharmaceutical Inc.
| 1 day | -0.12% | ||
| 1 week | +2.99% | ||
| Current month | +5.89% | ||
| 1 month | +8.72% | ||
| 3 months | +9.39% | ||
| 6 months | +4.05% | ||
| Current year | +0.74% |
| 1 week | 57.84 |  | 61.48 |
| 1 month | 54.06 | | 61.48 |
| Current year | 54.06 | | 61.88 |
| 1 year | 50.76 | | 73.51 |
| 3 years | 50.76 | | 108.44 |
| 5 years | 50.76 | | 117.77 |
| 10 years | 50.76 | | 131.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 57 | 2023-11-30 |
Brian Mueller
DFI | Director of Finance/CFO | 52 | 2020-01-28 |
Gregory Friberg
CTO | Chief Tech/Sci/R&D Officer | 52 | 2024-09-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Randy Meier
CHM | Chairman | 66 | 2023-11-30 |
Willard Dere
BRD | Director/Board Member | 72 | 2016-07-17 |
Robert Hombach
BRD | Director/Board Member | 60 | 2017-09-28 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 3.45% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.12% | +2.99% | -7.68% | -44.66% | 11.5B | |
| +2.49% | +2.25% | +19.24% | +6.75% | 82.42B | |
| +0.43% | +5.41% | +54.02% | +267.02% | 63.02B | |
| -0.52% | +71.00% | +71.00% | +71.00% | 54.86B | |
| +1.44% | -15.70% | -40.77% | -50.09% | 51.1B | |
| +0.52% | -2.32% | +43.10% | -29.56% | 28.84B | |
| +0.35% | -6.73% | +43.57% | +27.41% | 20.12B | |
| +0.56% | +12.08% | +137.60% | +114.96% | 19.67B | |
| +5.29% | +2.97% | +28.01% | -76.18% | 16.5B | |
| -0.44% | +2.53% | +28.42% | +71.37% | 15.76B | |
| Average | +1.04% | +0.43% | +37.65% | +35.80% | 36.38B | |
| Weighted average by Cap. | +1.09% | -0.14% | +34.22% | +55.07% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.18B 2.68B 2.45B 2.33B 4.34B 289B 4.5B 28.45B 11.31B 139B 11.93B 11.69B 488B | 3.4B 2.87B 2.62B 2.5B 4.64B 309B 4.81B 30.44B 12.1B 149B 12.77B 12.51B 523B |
| Net income | 478M 404M 368M 351M 652M 43.44B 676M 4.28B 1.7B 20.91B 1.79B 1.76B 73.43B | 797M 673M 613M 585M 1.09B 72.38B 1.13B 7.13B 2.83B 34.85B 2.99B 2.93B 122B |
| Net Debt | -1.42B -1.2B -1.09B -1.04B -1.94B -129B -2.01B -12.71B -5.05B -62.15B -5.33B -5.22B -218B | -1.74B -1.47B -1.34B -1.28B -2.37B -158B -2.46B -15.54B -6.18B -75.97B -6.52B -6.38B -267B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-13 | 59.87 $ | -0.12% | 1,941,042 |
| 26-02-12 | 59.94 $ | -0.61% | 4,416,395 |
| 26-02-11 | 60.31 $ | +1.09% | 2,646,655 |
| 26-02-10 | 59.66 $ | +3.20% | 3,329,750 |
| 26-02-09 | 57.81 $ | -0.55% | 1,314,789 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMRN Stock
Select your edition
All financial news and data tailored to specific country editions
